The double dose Trelegy Ellipta, which received approval in Korea for asthma, not COPD, may now be prescribed at general hospitals in Korea.

According to industry sources, GSK Korea's Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) has passed the drug committees (DCs) of the Big 5 tertiary hospitals in Korea, including Samsung Medical Center, Seoul National University Hospital, Seoul Asan Medical Center, and Sinchon Severance Hospital.

Trelegy 200 Ellipta, which was listed for reimbursement since March this year, may be prescribed to treat patients with "severe asthma that is not adequately controlled with a maintenance combination of a medium or high dose of an inh